- Home
- PYPD vs HHS Comparison
PYPD vs HHS Comparison
Compare PYPD & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- HHS
- Stock Information
- Founded
- PYPD 2008
- HHS 1923
- Country
- PYPD Israel
- HHS United States
- Employees
- PYPD N/A
- HHS N/A
- Industry
- PYPD Medical/Dental Instruments
- HHS Advertising
- Sector
- PYPD Health Care
- HHS Consumer Discretionary
- Exchange
- PYPD Nasdaq
- HHS Nasdaq
- Market Cap
- PYPD 35.3M
- HHS 30.3M
- IPO Year
- PYPD 2020
- HHS N/A
- Fundamental
- Price
- PYPD $3.58
- HHS $3.81
- Analyst Decision
- PYPD Strong Buy
- HHS
- Analyst Count
- PYPD 5
- HHS 0
- Target Price
- PYPD $11.40
- HHS N/A
- AVG Volume (30 Days)
- PYPD 1.4M
- HHS 28.9K
- Earning Date
- PYPD 08-13-2025
- HHS 08-07-2025
- Dividend Yield
- PYPD N/A
- HHS N/A
- EPS Growth
- PYPD N/A
- HHS N/A
- EPS
- PYPD N/A
- HHS N/A
- Revenue
- PYPD N/A
- HHS $181,355,000.00
- Revenue This Year
- PYPD N/A
- HHS $6.54
- Revenue Next Year
- PYPD N/A
- HHS N/A
- P/E Ratio
- PYPD N/A
- HHS N/A
- Revenue Growth
- PYPD N/A
- HHS N/A
- 52 Week Low
- PYPD $2.30
- HHS $3.24
- 52 Week High
- PYPD $4.49
- HHS $8.87
- Technical
- Relative Strength Index (RSI)
- PYPD 59.00
- HHS 38.74
- Support Level
- PYPD $3.12
- HHS $3.24
- Resistance Level
- PYPD $3.75
- HHS $4.20
- Average True Range (ATR)
- PYPD 0.29
- HHS 0.46
- MACD
- PYPD 0.01
- HHS -0.04
- Stochastic Oscillator
- PYPD 69.83
- HHS 26.51
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.